
S&P TEST

SWOT & PESTLE.com

GILEAD SCIENCES SWOT & PESTLE ANALYSIS

© Barakaat Consulting - An Ezzy IT Consulting Business

This is a licensed product and is not to be photocopied or distributed. All rights reserved. Unauthorized reproduction is strictly prohibited. Research is based on best available materials and resources. To purchase reprints of this document, please email support@swotandpestle.com.

Company Name : Gilead Sciences

Company Sector : Pharmaceuticals and Biotechnology

Operating Geography : United States, North America, Global

About the Company :

Gilead Sciences, Inc. is an American biopharmaceutical company that focuses primarily on antiviral drugs used in the treatment of Hepatitis B, Hepatitis C, HIV and influenza, including Sovaldi and Harvoni. It is headquartered at Foster City, California, United States. It was founded in June 1987 by Michael L. Riordan with the help of three core scientific advisers, Peter Dervan (Caltech), Doug Melton (Harvard) and Harold M. Weintraub (Fred Hutchinson Cancer Research Centre). The company has expanded to multiple drug segments through a series of strategic acquisitions starting from NeXstar Pharmaceuticals, Corus Pharma Inc. (2006), Raylo Chemicals Inc. (2006), CV Therapeutics (2009), CGI Pharmaceuticals (2010). The company's product portfolio includes more than 25 products including complete treatment regimens for HIV and Hepatitis C virus. Gilead was '2021 Facility of the Year Awards' winner for operational agility: COVID-19 impact. In August 2022, Gilead Sciences and MiroBio, a privately held biotechnology company based in the United Kingdom, signed a definitive deal under which Gilead will purchase MiroBio for about \$405 million in cash. MiroBio's exclusive discovery technology and comprehensive portfolio of immune inhibitory receptor agonists will be acquired by Gilead. As of 2023, Gilead has commercial sales operations in the US and globally, with subsidiaries in 35+ countries. Gilead's global workforce of over 16,000 employees across six continents is dedicated to improving global healthcare and fostering a better, healthier world.

The USP of Gilead Sciences lies in it being the market leader for HIV drugs globally. Gilead Sciences mission statement reads "To discover, develop and commercialize innovative therapeutics in the areas of unmet medical needs that improve patient care." The research based; biopharmaceutical company's vision is "To advance therapeutics against life-threatening diseases worldwide."

Revenue :

US\$27.2 billion – FY ending 31st December 2022 (y-o-y decline of 0.09%)

US\$27.3 billion – FY ending 31st December 2021 (y-o-y growth of 11%)

US\$24.6 billion - FY ending 31st December 2020

SWOT Analysis :

The SWOT Analysis for Gilead Sciences is given below:

Strengths	Weaknesses
1.Strong Brand Portfolio 2.Research and Development Orientation 3.Investments in process automation 4.Strategic Acquisitions and mergers	1.Inability to accurately predict demand 2.Declining product sales in HIV and HCV segment 3.Reliance on three wholesalers for marketing and distribution
Opportunities	Threats
1.High growth potential of the biopharmaceutical industry 2.Usage of Industry 4.0 technology 3.Expansion of footprint in various regions 4.Acquires XinThera to enhance oncology and inflammation pipeline 5.Expands collaboration for inflammatory disease therapies	1.Certain challenges related to patent protection 2.Regulation of manufacturing process 3.Complexity of biopharma supply chain and operations 4.High competition in the industry 5.Rising cases of counterfeit products 6.AIDS advocates pressure company over drug pricing

PESTLE Analysis :

The PESTLE Analysis for Gilead Sciences is given below:

Political	Economical
1.Impact of government legislative and regulatory actions 2.Compliance with FDA and other comparable international standards 3.Political advantage due to the joint venture with European Commission for Covid-19 treatment 4.Impact of Russia-Ukraine war 5.Reimbursement pressures from government agencies	1.Fluctuations in the foreign currency exchange rate 2.Interest rate and credit risk on company's portfolio 3.Impact of inflation reduction act
Social	Technological
1.Impact of aging population 2.Contribution of the pharma industries towards the treatment of Covid-19 3.Impact of public perception, awareness, and social stigma on disease awareness	1.Opportunities due to emerging innovations 2.Risks associated with cyber security 3.Revolutionizing healthcare- recent advancements and key innovations
Legal	Environmental
1.Non-infringement of patents and proprietary rights 2.Expensive litigation and government investigations	1.Green and Sustainable chemistry 2.Waste Reduction and Recycling

Please note that our free summary reports contain the SWOT and PESTLE table contents only.
The complete report for **Gilead Sciences** SWOT & PESTLE Analysis is a paid report at **12.53 U.S.D.**

Buy Now

* By clicking on "Buy Now" you agree to accept our "Terms and Conditions."

S&P

SWOT & PESTLE.com

SWOT & PESTLE.com is a leading strategy research portal covering detailed Strengths, Weaknesses, Opportunities, Threats (SWOT) and Political, Economic, Social, Technological, Legal and Environmental (PESTLE) analysis of leading industry sectors and organizations across the globe. Our full and comprehensive collection on SWOT and PESTLE has been written by our team of professional analysts consisting of MBA's, CFA's and industry experts. Our analysis has helped businesses, researchers and scholars with valuable insights to make strategic decisions and take their research forward.

We at SWOT & PESTLE.com aim to aid the understanding of the multifaceted business world by presenting a list of diverse companies from across the globe. Business organizations today cannot function in ways that ignore the surroundings that they are set in. SWOT & PESTLE.com makes a keen observation into this aspect and accounts for factors affecting such businesses.

Copyright Notice

The information provided in the SWOT and PESTLE research reports on www.swotandpestle.com are from publicly available documents and sources which are deemed reliable. Further the reports contain analysis and views from the SWOT & PESTLE.com research and analyst team which consists of qualified experts. While every attempt has been made to ensure completeness, accuracy and reliability of the analysis, Barakaat Consulting and its associate websites cannot be held responsible or legal liable for omissions or errors in our reports or on any of our pages.

(C)2024 Barakaat Consulting. All rights reserved. This report may not be reproduced, copied or redistributed, in whole or in part, in any form or by any means, without the express written consent of Barakaat Consulting. Also, Barakaat Consulting is the sole copyright owner of this report, and any use of this report by any third party is strictly prohibited without a license expressly granted by Barakaat Consulting. Neither all nor any part of the contents of this report, or any opinions expressed herein, can be used in advertising, press releases, or promotional materials without prior written approval from Barakaat Consulting. Any violation of Barakaat Consultings rights in this report will be executed to the fullest extent of the law, including the pursuit of monetary damages and injunctive relief in the event of any breach of the foregoing restrictions.

Client Support:
support@swotandpestle.com